Cinctive Capital Management LP Has $2.06 Million Position in Celldex Therapeutics, Inc. (NASDAQ:CLDX)

Cinctive Capital Management LP increased its holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 140.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 81,320 shares of the biopharmaceutical company's stock after acquiring an additional 47,523 shares during the period. Cinctive Capital Management LP owned about 0.12% of Celldex Therapeutics worth $2,055,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of CLDX. Values First Advisors Inc. lifted its position in shares of Celldex Therapeutics by 20.0% in the fourth quarter. Values First Advisors Inc. now owns 29,009 shares of the biopharmaceutical company's stock worth $733,000 after purchasing an additional 4,837 shares in the last quarter. BNP Paribas Financial Markets boosted its stake in shares of Celldex Therapeutics by 293.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 28,181 shares of the biopharmaceutical company's stock valued at $958,000 after buying an additional 21,013 shares during the period. Barclays PLC grew its holdings in shares of Celldex Therapeutics by 140.7% during the 3rd quarter. Barclays PLC now owns 130,381 shares of the biopharmaceutical company's stock valued at $4,431,000 after acquiring an additional 76,207 shares in the last quarter. XTX Topco Ltd acquired a new position in shares of Celldex Therapeutics in the third quarter worth $1,561,000. Finally, SG Americas Securities LLC raised its holdings in shares of Celldex Therapeutics by 24.4% during the fourth quarter. SG Americas Securities LLC now owns 25,283 shares of the biopharmaceutical company's stock worth $639,000 after acquiring an additional 4,967 shares in the last quarter.

Wall Street Analyst Weigh In

Several research analysts have weighed in on CLDX shares. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $67.00 target price on shares of Celldex Therapeutics in a research report on Wednesday, January 29th. HC Wainwright restated a "buy" rating and issued a $80.00 price objective on shares of Celldex Therapeutics in a report on Friday, February 28th. Morgan Stanley initiated coverage on shares of Celldex Therapeutics in a research note on Thursday, March 20th. They issued an "overweight" rating and a $46.00 target price for the company. The Goldman Sachs Group cut their price target on shares of Celldex Therapeutics from $42.00 to $36.00 and set a "neutral" rating on the stock in a report on Monday, March 3rd. Finally, UBS Group started coverage on shares of Celldex Therapeutics in a report on Thursday, February 13th. They issued a "buy" rating and a $44.00 price objective for the company. Two equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $54.33.

Celldex Therapeutics Trading Up 2.3 %

CLDX traded up $0.37 during trading on Tuesday, hitting $16.10. The stock had a trading volume of 277,497 shares, compared to its average volume of 868,051. The firm has a market cap of $1.07 billion, a PE ratio of -6.26 and a beta of 1.59. Celldex Therapeutics, Inc. has a 12 month low of $14.61 and a 12 month high of $47.00. The company has a 50 day simple moving average of $21.01 and a 200-day simple moving average of $25.16.

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last posted its quarterly earnings data on Thursday, February 27th. The biopharmaceutical company reported ($0.71) earnings per share for the quarter, topping the consensus estimate of ($0.73) by $0.02. The business had revenue of $1.18 million during the quarter, compared to analysts' expectations of $1.25 million. Celldex Therapeutics had a negative return on equity of 19.75% and a negative net margin of 1,544.32%. As a group, sell-side analysts anticipate that Celldex Therapeutics, Inc. will post -2.48 earnings per share for the current fiscal year.

Celldex Therapeutics Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.